Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. - Wikidata - wikimedia - TriplyDB

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

http://www.wikidata.org/entity/Q35089983

about

Prostate cancer screening in Brazil: should it be done or not?The ProCaSP study: quality of life outcomes of prostate cancer patients after radiotherapy or radical prostatectomy in a cohort study.The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.Serum markers in prostate cancer detection Automated prostate cancer detection via comprehensive multi-parametric magnetic resonance imaging texture feature models.Quantifying disparities in cancer incidence and mortality of Australian residents of New South Wales (NSW) by place of birth: an ecological study.Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.Isolation and analysis of discreet human prostate cellular populations Personalized prostate cancer care: from screening to treatment.Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS.Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells.Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men.Who and when should we screen for prostate cancer? Interviews with key opinion leaders.Recommandations de l’Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate.Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.Prostate cancer clinical presentation, incidence, mortality and survival in Guadeloupe over the period 2008-2013 from a population-based cancer registry.Prostate imaging--the future is now: current concepts and future potentials.Screening for prostate cancer in the US? Reduce the harms and keep the benefit.Prostate cancer screening-when to start and how to screen?Risk of Breast, Prostate, and Colorectal Cancer Diagnoses Among HIV-Infected Individuals in the United States.Chelerythrine induced cell death through ROS-dependent ER stress in human prostate cancer cells.Effects of connective tissue growth factor on prostate cancer bone metastasis and osteoblast differentiation.Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer

P2860

Q28068688-F09AAAD0-0F26-45FE-B5BB-42F26D9A1ACF Q30641961-9B066FB6-06B4-4202-BA64-D6E5BA8CF7C6 Q34512629-5D38DAC4-EC16-45C4-96D3-6B6FA5465D3D Q35042519-0CC64821-1895-4FE6-8FB4-4169B9933F4B Q35737796-50D8F2C5-A983-4A50-8754-D97EBBB34255 Q35755246-9CEE5504-CC02-4726-BD91-72A5E25E45AA Q35944835-CE304974-82A7-4207-A1F6-00F07471AE53 Q36051375-CDB406A6-349D-442F-A936-5C4686762541 Q36863464-6965B62F-8631-41C1-846B-F58EA5C27C42 Q37113160-3E32718F-5DD9-4FCE-89A5-FFB3EEF06445 Q37418080-95424AB6-4728-47F9-AD57-29A4960E5084 Q37563750-8CA5BEA0-F7F5-459F-9F85-C9BE0AD1BD42 Q38725529-F36627A2-361E-4D81-9076-753C5D82E278 Q39559217-B9D7DA75-0FB7-4AA3-9F23-A1C65E2795F2 Q40180148-BCF65B78-F1BF-43F8-BEAC-FAE384E7594B Q43152601-9581546A-207A-4856-A758-01679EBFAD62 Q47123251-0357B86B-61FA-47EC-AF58-140C89759362 Q48165110-2ADF85DF-CA26-4FE2-A83E-1783790FDEC2 Q48333499-7097F328-458B-4742-AADB-20E89632481D Q48853490-84CEB086-4733-4C68-8102-3E236C5E1220 Q51063097-212786DC-8F3C-41CC-B9CE-7228289B0A20 Q52624230-D02E2211-04D8-4322-A9C2-CF8173FC8A52 Q52660669-C6D92531-D6A2-4364-89A3-39720419A1A2 Q54108544-7B3D4565-D04B-481F-8872-665E35B94F23 Q55644712-E3B2535D-18CD-4F7B-B375-1327CD6EDCEE Q58773054-35D7785F-C183-4834-8B62-6D537E89BBE7

P2860

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

http://www.wikidata.org/entity/Q35089983

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Empirical estimates of prostat ...... and prostate-specific antigen.

@ast

Empirical estimates of prostat ...... and prostate-specific antigen.

@en

type

label

Empirical estimates of prostat ...... and prostate-specific antigen.

@ast

Empirical estimates of prostat ...... and prostate-specific antigen.

@en

prefLabel

Empirical estimates of prostat ...... and prostate-specific antigen.

@ast

Empirical estimates of prostat ...... and prostate-specific antigen.

@en

P1433

Q35089983-58F03A36-D1EF-43F1-A4E9-FD2332C5CC9D

P1476

Q35089983-8DA35B5D-A9E1-4BF8-9A69-815BA5339225

P2093

Q35089983-13160B87-C564-4351-9DAA-F2C97DAD4C99

Q35089983-5E5301D5-1901-4EE8-8DE1-28EDE0057012

Q35089983-979FA4A3-D03A-4BD5-AFA8-77DDE2B3E9F1

Q35089983-E405A88D-5DE8-406F-A704-CBAF8CD716FD

Q35089983-FC6CAACE-B5D0-409A-999D-217E57832D16

Q35089983-FDD8220B-378B-442F-81E0-AC192C027428

P2860

Q35089983-0A5F392D-8EFE-41EA-B059-DD56F3FEB4F4

Q35089983-0FFA4028-1C4A-4C34-B80D-7DDBA0008426

Q35089983-192AB286-299F-49F4-A35C-ABE2149EEF24

Q35089983-1F418DED-A039-4CBF-BF7B-D435683E1FF8

Q35089983-23160E51-0B36-4E0B-83C3-5C80A590BB21

Q35089983-2354A468-6A95-4715-B581-50E0E4C257E3

Q35089983-41E4A325-12FA-40EB-9675-17542E0B22C8

Q35089983-4DE706F2-5636-402D-8074-7AC42C87103E

Q35089983-50153E72-C3EC-4621-96A7-F5EEA9A5E212

Q35089983-5B0809B1-5B0B-459D-99F4-646C9B03531A

P2888

Q35089983-C27931EE-C842-4D09-907A-3163BFDEB245

P304

Q35089983-D6415B04-1C8F-4099-8F83-FE47252FD325

P31

Q35089983-C1F2A62E-7620-44D7-B2C7-98A40BA0DDE0

P356

Q35089983-2244391B-4D8F-4DB7-ACA5-68DC59D7F70D

P407

Q35089983-88109137-6C27-4A9D-8475-536107B2D88A

P478

Q35089983-04CBDDA4-4106-4860-B1A3-9E33A3704339

P50

Q35089983-223AA5BD-F047-422F-88A1-A2B65414F433

Q35089983-3809A361-7E84-4321-BCF1-4F6E6B04CBB3

Q35089983-672C1A26-9A15-4407-8FF1-6A9142EA3119

Q35089983-BDC83B0E-04A9-47F7-83D7-BD82671A38D0

Q35089983-EE7D64DB-3E48-4D57-84F9-488EA2ED5562

P577

Q35089983-45546016-FF6F-4882-A5BE-89CF6F4E138D

P5875

Q35089983-20723DDD-1DCD-4825-9874-65458D7DA691

P6179

Q35089983-25682251-0C05-4EE0-BF4E-63321C118F2C

P698

Q35089983-326EB7D5-E4C7-4394-8EBD-C81539FD822C

P932

Q35089983-A35516CF-856C-464E-939A-BD300390246A

P356

1741-7015-12-26

P1433

P1476

Empirical estimates of prostat ...... and prostate-specific antigen.

@en

P2093

Coral Atoria-Swartz

http://www.w3.org/2001/XMLSchema#string

Daniel D Sjoberg

http://www.w3.org/2001/XMLSchema#string

Eveline A M Heijnsdijk

http://www.w3.org/2001/XMLSchema#string

Harry De Koning

http://www.w3.org/2001/XMLSchema#string

Ian Thompson

http://www.w3.org/2001/XMLSchema#string

Peter T Scardino

http://www.w3.org/2001/XMLSchema#string

P2860

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005

Cancer statistics, 2013

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Prostate-cancer mortality at 11 years of follow-up.

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Quality-of-life effects of prostate-specific antigen screening.

Clinical risk factors, DNA variants, and the development of type 2 diabetes.

Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial

P2888

1741-7015-12-26

P304

26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1741-7015-12-26

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Andrew J Vickers

Emily Vertosick

P577

2014-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260151661

http://www.w3.org/2001/XMLSchema#string

P6179

1020023409

http://www.w3.org/2001/XMLSchema#string

P698

24512643

http://www.w3.org/2001/XMLSchema#string

P932

3922189

http://www.w3.org/2001/XMLSchema#string